Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Globe Newswire•28/09/2026•09:30 ET
0
Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study
Company expects to have sufficient Part A data to provide an interim clinical update by year-end 2026
Get started
Create a free account to read the full story and Whiz Insights.